Abstract
Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUA1) radiolabelled with iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions. Ten out of 13 effusions (3 pericardial and 7 pleural) responded completely with no fluid reaccumulation between 3 and 18 months. No clinical or other toxicity was observed. This new method of treatment for recurrent malignant effusions is non-toxic and effective resulting in improved quality of life, and, in some cases, prolongation of survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Pectasides, D., Stewart, S., Courtenay-Luck, N. et al. Antibody-guided irradiation of malignant pleural and pericardial effusions. Br J Cancer 53, 727–732 (1986). https://doi.org/10.1038/bjc.1986.125
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.125
This article is cited by
-
Pericardial fluid: an underrated molecular library of heart conditions and a potential vehicle for cardiac therapy
Basic Research in Cardiology (2019)
-
Synthesis of astatine-tagged methylene blue, a compound for fighting micrometastases and individual cells of melanoma
Journal of Radioanalytical and Nuclear Chemistry (1998)
-
Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption
Medical & Biological Engineering & Computing (1994)
-
Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution
Urological Research (1993)
